share_log

藥明康德：海外監管公告

WUXI APPTEC: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Mar 18 10:31
Summary by Moomoo AI
药明康德（股份代號：2359）於2024年3月18日發布了2023年度募集資金存放與實際使用情況的專項報告。報告顯示，公司在A股首次公開發行中募集資金總額為人民幣22.5億元，扣除發行費用後，實際募集資金淨額為人民幣21.3億元。截至2022年12月31日，已累計使用募集資金約人民幣18.6億元，並產生利息收入及理財收入淨額約人民幣1.22億元。公司已將剩餘募集資金約人民幣1.47億元全部存放於監管銀行。2023年3月20日，公司召開董事會及監事會年度會議，決定將A股首次公開發行募投項目整體結項，並將節餘募集資金永久補充流動資金，相關募集資金專戶已注銷。此外，2020年A股非公開發行中，公司募...展開全部
药明康德（股份代號：2359）於2024年3月18日發布了2023年度募集資金存放與實際使用情況的專項報告。報告顯示，公司在A股首次公開發行中募集資金總額為人民幣22.5億元，扣除發行費用後，實際募集資金淨額為人民幣21.3億元。截至2022年12月31日，已累計使用募集資金約人民幣18.6億元，並產生利息收入及理財收入淨額約人民幣1.22億元。公司已將剩餘募集資金約人民幣1.47億元全部存放於監管銀行。2023年3月20日，公司召開董事會及監事會年度會議，決定將A股首次公開發行募投項目整體結項，並將節餘募集資金永久補充流動資金，相關募集資金專戶已注銷。此外，2020年A股非公開發行中，公司募集資金總額為人民幣65.3億元，扣除發行費用後，實際募集資金淨額為人民幣64.6億元。截至2023年12月31日，已累計使用募集資金約人民幣63.9億元。公司決定將2020年A股非公開發行募投項目整體結項，並將節餘募集資金約人民幣1.08億元永久補充公司流動資金。會計師事務所對公司年度募集資金存放與使用情況出具的鑑證報告結論性意見認為，药明康德的募集資金存放與實際使用情況已按照相關規定編制，真實反映了公司募集資金的使用情況。
Ming Kand Pharmaceuticals (stock code: 2359) issued a special report on the storage and actual use of funds raised for 2023 on March 18, 2024. The report showed that the company raised total funds in the initial public offering of A shares was RMB22.5 billion, and net actual fundraising was RMB21.3 billion after deduction of issuance costs. As of December 31, 2022, approximately RMB18.6 billion has been used to raise funds and generated net interest income and banking income of approximately RMB1.22 million. The company has deposited all of the remaining funds raised by about RMB 1.47 million with regulated banks. On March 20, 2023, the Company held an annual meeting of the Board of Directors and Supervisory Board to resolve the overall conclusion of the Initial Public Offering of A Shares and...Show More
Ming Kand Pharmaceuticals (stock code: 2359) issued a special report on the storage and actual use of funds raised for 2023 on March 18, 2024. The report showed that the company raised total funds in the initial public offering of A shares was RMB22.5 billion, and net actual fundraising was RMB21.3 billion after deduction of issuance costs. As of December 31, 2022, approximately RMB18.6 billion has been used to raise funds and generated net interest income and banking income of approximately RMB1.22 million. The company has deposited all of the remaining funds raised by about RMB 1.47 million with regulated banks. On March 20, 2023, the Company held an annual meeting of the Board of Directors and Supervisory Board to resolve the overall conclusion of the Initial Public Offering of A Shares and to permanently supplement the remaining fund raising funds with liquidity, which has been transferred to the respective fund raising pool. In addition, in the 2020 A-share non-public issue, the company raised a total of RMB65.3 billion, and net actual fundraising was RMB64.6 billion after the issuance costs. As of 31 December 2023, approximately RMB63.9 billion has been used in fundraising. The Company decided to close the A-share non-public offering in 2020 and to permanently supplement the Company's liquidity with the remaining fund raising of approximately RMB1.08 million. THE FIRM'S CONCLUSIVE OPINION ON THE ASSESSMENT REPORT ON THE COMPANY'S ANNUAL FUND-RAISING HOLDINGS AND USE IS THAT THE STORAGE AND ACTUAL USE OF FUNDRAISING FUNDS AT THE COMPANY'S ANNUAL FUNDRAISING HAS BEEN FORMULATED IN ACCORDANCE WITH THE RELEVANT REGULATIONS AND TRULY REFLECTS THE USE OF THE COMPANY'S FUNDRAISING FUNDS.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more